A Phase I Study of SIM0388 in Participants With Malignant Ascites.

Recruiting now · Phase 1

Conditions studied: Malignant Ascites

In brief

Malignant Ascites is a common complication of malignant tumor. The objective of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of intraperitoneal perfusion with Docetaxel Polymeric Micelles (SIM0388) for injection in patients with malignant ascites

Key facts

Study ID

NCT07007988

Run by

Jiangsu Simcere Pharmaceutical Co., Ltd.

People needed

50

Starts

2025-04-24

Expected to finish

2027-12-01

Last updated by the study team

2025-06-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Voluntary participation and signature of informed consent form;.
• ≥ 18 years of age, male or female.
• Participants with histologically and/or cytologically confirmed advanced/metastatic solid tumors;.
• Failure of at least one line of standard systemic anti-tumor therapy, unsuitability for standard systemic therapy, or absence of standard systemic therapy options.
• Moderate or greater ascites confirmed by ultrasonography
• ECOG performance status of 0, 1or 2.
• Life expectancy ≥ 3 months.
• Adequate hematologic and organ function.
• Women of childbearing potential (WOCBP) must have a negative serum pregnancy test. WOCBP and male subjects agree to use adequate contraception.

You may not qualify if…

• Participant is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of first dose of study treatment
• Prior history of intraperitoneal paclitaxel-based therapy.
• Use of strong CYP3A4 inhibitors or inducers within 7 days before the first dose or anticipated use during the study.
• Failure to recover from adverse events caused by prior interventions to ≤Grade 1
• Complete intestinal obstruction within 30 days prior to the first dose.
• Myocardial infarction within 6 months, current unstable angina, primary cardiomyopathy, cerebrovascular events, congestive heart failure, symptomatic coronary artery disease requiring medication, arrhythmia requiring medication, QTcF interval >470 ms, or uncontrolled hypertension.
• Uncontrolled primary brain tumors or CNS metastases.
• Active infection.
• Known history of HIV infection.
• Active hepatitis B or hepatitis C infection.
• Hypersensitivity to any active or inactive ingredient of SIM0388.
• Pregnant or lactating women.
• Any condition (medical history, disease, treatment, or lab abnormality) that may interfere with study results, impede full participation, or deemed by the investigator to contradict the subject's best interests.

Where it is running

• Shanghai Gobroad Cancer Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.